BRAF and melanoma: Garmpis et al. (58) proposed to investigate the synergistic effect of HDACi (Vorinostat (5AIIA, Zalmza), Romidepsin (Istodox, Depsipeptide), Belinostat and Panobinostat (Farydak) with other inhibitors such as BRAF inhibitors and BET inhibitors, which may lead to melanoma treatment.